CX 2016 Presentations
PERIPHERAL ARTERIAL CHALLENGES - Day 1
Tuesday 26 April
Introduction Iris Baumgartner, Bern, Switzerland 08:00 to 08:40
Chairman Cliff Shearman, Southampton, United Kingdom 08:00 to 08:40
Exercise therapy for claudicants - the guidance from NICE and other healthcare regulators is being ignored Jonathan Beard, Sheffield, United Kingdom 08:00 to 08:07
Wearable exercise tracker improves intermittent claudication Celia Riga, London, United Kingdom 08:07 to 08:14
Hypertension and the risk of peripheral arterial disease Kazem Rahimi, Oxford, United Kingdom 08:14 to 08:21
Debulking of arterial occlusions (Rotarex) Michael Lichtenberg, Arnsberg, Germany 08:21 to 08:28
Audience participation and discussion Jacques Busquet, Paris St Cloud, France 08:28 to 08:40
Chairman Roger Greenhalgh, London, United Kingdom 08:40 to 14:46
Superficial femoral artery Frans Moll, Utrecht, Netherlands 08:40 to 14:46
Rationale, evidence and indication for plaque modification before drug-coated balloon Erwin Blessing, Heidelberg, Germany 08:40 to 08:48
Technique and role of predilation in drug-coated balloon practice Stephan Duda, Berlin, Germany 08:48 to 08:56
Audience participation and discussion 08:56 to 09:04
Podium 1st: IN.PACT SFA two-year results - drug-coated balloon use in women and in diabetics Peter Schneider, Honolulu, United States 09:04 to 09:12
Arterial wall response to drug-coated balloon use Renu Virmani, Gaithersburg, United States 09:12 to 09:20
Outcomes from the German cohort in Levant 2 with procedural key issues Dierk Scheinert, Leipzig, Germany 09:20 to 09:28
Audience participation and discussion 09:28 to 09:36
ILLUMENATE global study - interim analysis Thomas Zeller, Bad Krozingen, Germany 09:36 to 09:44
Podium 1st : IN.PACT Global drug-coated balloon for complete total occlusion Gunnar Tepe, Rosenheim, Germany 09:44 to 09:52
Audience participation and discussion 09:52 to 10:00
Chairman Ramon Varcoe, Sydney, Australia 09:52 to 10:00
Stent characteristics overcome calcified lesions Enrique Puras Mallagray, Madrid, Spain 10:03 to 10:12
Economic benefit from avoiding reintervention Michael Jaff, Boston, United States 10:12 to 10:21
Audience participation and discussion 10:21 to 10:30
Chairman Roger Greenhalgh, London, United Kingdom 10:30 to 11:18
Stent challenges Giovanni Torsello, Muenster, Germany 10:30 to 11:18
Swirling flow is the aim for durable results Peter Gaines, Sheffield, United Kingdom 10:30 to 10:38
Radial strength and stent design can overcome calcified lesions Peter Goverde, Antwerp, Belgium 10:38 to 10:46
Zilver PTX - five-year results show the value of stent drug elution Michael Dake, Stanford, United States 10:46 to 10:54
The value of polymer release and paclitaxel combination with drug-eluting stents Juan Granada, Orangeburg, United States 10:54 to 11:02
Audience participation and discussion 11:02 to 11:18
Chairman Roger Greenhalgh, London, United Kingdom 11:18 to 12:30
The challenges of the long lesion Giovanni Torsello, Muenster, Germany 11:18 to 12:30
Drug-coated balloons for lesions >15cm Michael Jaff, Boston, United States 11:18 to 11:26
Atherectomy and drug-coated balloon for long and calcified lesions Thomas Zeller, Bad Krozingen, Germany 11:26 to 11:34
Sequential stents for long lesions Donald Jacobs, St. Louis, United States 11:34 to 11:42
Audience participation and discussion 11:42 to 11:54
Subintimal stent use for critical ischaemia and biphasic wave forms Luis Mariano Palena, Abano Terme, Italy 11:54 to 12:02
The use of a single long stent Peter Goverde, Antwerp, Belgium 12:02 to 12:10
The use of stent graft as a priority for lesions greater than 25cm Jorge Fernandez Noya, Santiago Compostela, Spain 12:10 to 12:18
Audience participation and discussion 12:18 to 12:30
Chairman Michael Jaff, Boston, United States 12:30 to 13:00
IN.PACT SFA two-year results of drug-coated balloon William Gray, Wynnewood, United States 12:33 to 12:42
EU healthcare economic analysis of IN.PACT SFA use Konstantinos Katsanos, London, United Kingdom 12:42 to 12:51
Audience participation and discussion 12:51 to 12:58
The challenges of in-stent restenosis Andrew Holden, Auckland, New Zealand 13:30 to 14:46
Chairman Frans Moll, Utrecht, Netherlands 13:30 to 14:46
Drug-coated balloons for in-stent restenosis Marianne Brodmann, Graz, Austria 13:30 to 13:37
Patterns are different for bare metal stent and drug-eluting stent which affect ease of management Gary Ansel, Columbus, United States 13:37 to 13:44
Any stent restenosis treated by stent graft Jeffrey Y Wang, Rockville, United States 13:44 to 13:51
Audience participation and discussion 13:51 to 14:01
Zilver PTX - interpretations of restenosis Thomas Zeller, Bad Krozingen, Germany 14:01 to 14:08
Treatment of iliac in-stent restenosis with laser debulking and covered stents Jos van den Berg, Lugano, Switzerland 14:08 to 14:15
Angioplasty alone or drug-coated balloon or laser debulk/drug-coated balloon for in-stent restenosis Eric Ducasse, Bordeaux, France 14:15 to 14:22
Ten-year follow-up of 1,000 patients with heparin-bonded PTFE Raffaele Pulli, Firenze, Italy 14:22 to 14:29
Audience participation and discussion 14:29 to 14:46
Popliteal aneurysm Andrew Holden, Auckland, New Zealand 14:46 to 14:58
Chairman Frans Moll, Utrecht, Netherlands 14:46 to 14:58
Popliteal aneurysm sac volume shrinkage after stent graft Michele Antonello, Padua, Italy 14:46 to 14:54
Audience participation and discussion 14:54 to 14:58
Audience participation and discussion 14:54 to 14:58
Below-the-knee Andrew Holden, Auckland, New Zealand 14:58 to 18:00
Chairman Frans Moll, Utrecht, Netherlands 14:58 to 18:00
Perfusion angiography for ischaemic tissue Jim Reekers, Amsterdam, Netherlands 14:58 to 15:06
Audience participation and discussion 15:06 to 15:14
Multi-modality advanced imaging for severe peripheral ischaemia Koen Deloose, Dendermonde, Belgium 15:14 to 15:22
Audience participation and discussion 15:22 to 15:30
Chairman Thomas Zeller, Bad Krozingen, Germany 16:00 to 16:52
Below-the-knee (Cont'd) Peter Schneider, Honolulu, United States 16:00 to 16:52
MRA calf perfusion before and after angioplasty Gerd Groezinger, Tubingen, Germany 16:00 to 16:08
First experience with a bioresorbable, Everolimus-eluting vascular scaffold in arteries below-the-knee Ramon Varcoe, Sydney, Australia 16:08 to 16:16
Angiosome concept in the treatment of critical limb ischaemia Maarit Venermo, Helsinki, Finland 16:16 to 16:24
A novel solution for below-the-knee arterial clot management for acute ischaemia Roberto Gandini, Rome, Italy 16:24 to 16:32
Ten-year results of pedal bypass surgery Anders Alback, Helsinki, Finland 16:32 to 16:40
Audience participation and discussion 16:40 to 16:52
Chairman Michael Edmonds, London, United Kingdom 16:52 to 18:00
Mini-symposium: Wound healing Cliff Shearman, Southampton, United Kingdom 16:52 to 18:00
The need to measure wound healing William Jeffcoate, Nottingham, United Kingdom 16:52 to 17:00
Early detection of ulceration in diabetic feet - an intelligent telemedicine system Jeff van Baal, ALMELO, Netherlands 17:00 to 17:08
The enduring principles of ulcer and wound healing in the ischaemic lower limb Malcolm Simms, Birmingham, United Kingdom 17:08 to 17:16
The use of autologous cell suspension for complex diabetic wounds Harvey Chant, Truro, United Kingdom 17:16 to 17:24
Adjunctive techniques including offloading and hyperbaric oxygen Andrew Boulton, Manchester, United Kingdom 17:24 to 17:32
Pulsating negative pressure to increase peripheral blood flow - mechanisms and potential clinical benefit Jonny Hisdal, Oslo, Norway 17:32 to 17:40
Audience participation and discussion 17:40 to 18:00
VENOUS CHALLENGES - Day 1 Tuesday 26 April
Chairman Stephen Black, East Horsley, United Kingdom 08:00 to 08:24
Deep vein thrombosis challenges Ian Franklin, London, United Kingdom 08:00 to 08:24
Protection from embolisation using Capturex Thomas Heller, Rostock, Germany 08:00 to 08:08
Vena cava filter Celect Platinum Richard McWilliams, Liverpool, United Kingdom 08:08 to 08:16
Audience participation and discussion 08:16 to 08:24
Acute deep vein thrombosis challenges Stephen Black, East Horsley, United Kingdom 08:24 to 14:18
Chairman Ian Franklin, London, United Kingdom 08:24 to 14:18
From venous thrombosis to post thrombotic syndrome Marzia Lugli, Modena, Italy 08:24 to 08:32
Deep vein thrombosis (DVT) in pregnancy Wilhelm Sandmann, Duisburg, Germany 08:32 to 08:40
Conservative management of DVT Gerry Stansby, Newcastle-upon-Tyne, United Kingdom 08:40 to 08:48
Investigating patients with acute DVT Karen Breen, London, United Kingdom 08:48 to 08:56
Ageing deep vein thrombosis Brahman Dharmarajah, London, United Kingdom 08:56 to 09:04
Audience participation and discussion 09:04 to 09:12
Selection of patients for acute DVT intervention Carsten Arnoldussen, Maastricht, Netherlands 09:12 to 09:20
Strategies for clot removal, lysis and mechanical thrombectomy Robert Thomas, London, United Kingdom 09:20 to 09:28
Deep venous catheter design (Zelante) for deep venous thrombectomy Gerard O'Sullivan, Galway, Ireland 09:28 to 09:36
Endovascular treatment for acute DVT and pulmonary embolism - Indigo System Michael Lichtenberg, Arnsberg, Germany 09:36 to 09:44
Detachment of occlusive thrombus in deep vein, aspiration, fragmentation and removal - Aspirex Thomas Heller, Rostock, Germany 09:44 to 09:52
Audience participation and discussion 09:52 to 10:00
Chairman Frans Moll, Utrecht, Netherlands 10:30 to 11:30
Acute deep vein thrombosis challenges (Cont'd) Gerry Stansby, Newcastle-upon-Tyne, United Kingdom 10:30 to 11:30
Deep vein stenting challenges 10:30 to 11:30
It is not just about patency - scales and quality of life outcomes Alun Davies, London, United Kingdom 10:30 to 10:38
VIDIO Trial - IVUS significantly improves diagnostic accuracy Paul Gagne, Darien, United States 10:38 to 10:46
Factors influencing outcome in venous stenting Stephen Black, East Horsley, United Kingdom 10:46 to 10:54
From lab to patient - strategies to improve stent patency Prakash Saha, London, United Kingdom 10:54 to 11:02
VIRTUS trial update on iliofemoral venous outflow obstruction Lowell Kabnick, Morristown, United States 11:02 to 11:10
Zilver Vena trial "first glimpse" Gerard O'Sullivan, Galway, Ireland 11:10 to 11:18
Audience participation and discussion 11:18 to 11:30
Proximal deep venous obstruction and pelvic vein reflux challenges 11:30 to 13:30
Deep venous stenting before superficial venous intervention Ian Franklin, London, United Kingdom 11:30 to 11:38
Selection of patients for pelvic vein intervention - which patients to treat and which patients to manage conservatively? Kathleen Gibson, Bellevue, United States 11:38 to 11:46
Male pattern pelvic reflux Previn Diwakar, Congleton, United Kingdom 11:46 to 11:54
Implications of pelvic vein embolisation for subsequent pregnancies Anthony Lopez, Guildford, United Kingdom 11:54 to 12:02
Pelvic vein embolisation for treatment of haemorrhoids David Beckett, Guildford, United Kingdom 12:02 to 12:10
Pathogenesis of haemorrhoids - colorectal surgeon's perspective Peter Dawson, London, United Kingdom 12:10 to 12:18
Audience participation and discussion 12:18 to 12:30
Chairman Mark Whiteley, Guildford, United Kingdom 13:30 to 14:18
Lymphoedema challenges Ian Franklin, London, United Kingdom 13:30 to 14:18
Lipoedema vs. lymphoedema Peter Mortimer, London, United Kingdom 13:38 to 13:46
Real-time, point-of-care lymphatic imaging Eva Sevick, Houston, United States 13:46 to 13:54
Silicone tubule implants for lower limb lymphoedema Rajesh Hydrabadi, Ahmedabad, India 13:54 to 14:02
Audience participation and discussion 14:02 to 14:18
Varicose vein challenges Mark Whiteley, Guildford, United Kingdom 14:18 to 17:30
Chairman Ian Franklin, London, United Kingdom 14:18 to 17:30
Ultrasound placed percutaneous clips will make CHIVA more widely applicable Lowell Kabnick, Morristown, United States 14:18 to 14:26
VeClose randomised controlled trial two-year follow-up Raghu Kolluri, Columbus, United States 14:26 to 14:34
Differences between great, small, accessory saphenous and Giacomini veins in terms of choice of technique for treating venous reflux Steve Elias, Englewood, United States 14:34 to 14:42
Audience participation and discussion 14:42 to 14:50
The future of bipolar radiofrequency thermal ablation Thomas Weiler, Pforzheim, Germany 14:50 to 14:58
The need to correct the accessory thigh vein and great saphenous vein even if only one incompetent Lowell Kabnick, Morristown, United States 14:58 to 15:06
Quality of life results in the use of cyanoacrylate adhesive embolisation Kathleen Gibson, Bellevue, United States 15:06 to 15:14
Audience participation and discussion 15:14 to 15:22
Chairman Manj Gohel, Cambridge, United Kingdom 15:33 to 15:58
eScope clinical trial - two and three year follow-up Thomas Proebstle, Hirschberg, Germany 15:33 to 15:42
VeClose roll-in patient results Raghu Kolluri, Columbus, United States 15:42 to 15:51
Audience participation and discussion 15:51 to 15:58
Chairman Alun Davies, London, United Kingdom 16:00 to 17:30
Varicose vein challenges (continued) Ian Franklin, London, United Kingdom 16:00 to 17:30
Role of antibiotics in varicose vein treatment Ian Chetter, Hull, United Kingdom 16:00 to 16:08
Venous wall thickness determines optimal choice of endovenous treatment Mark Whiteley, Guildford, United Kingdom 16:08 to 16:16
Management of anatomically difficult revascularisation Barrie Price, Guildford, United Kingdom 16:16 to 16:24
Anti-DVT prophylaxis for ambulatory varicose vein procedures Isaac Nyamekye, Worcester, United Kingdom 16:24 to 16:32
Sclerotherapy of the subulcer plexus - practical tips for success Manj Gohel, Cambridge, United Kingdom 16:32 to 16:40
Audience participation and discussion 16:40 to 16:48
Compression film bandage after sclerotherapy Johann Christof Ragg, Berlin, Germany 16:48 to 16:56
Strategies for getting the best cosmetic results for thread vein/telangiectasia treatment Thomas Proebstle, Hirschberg, Germany 16:56 to 17:04
Laser treatment of reticular and subcuticular veins Kasuo Miyake, Sao Paulo, Brazil 17:04 to 17:12
Evidence of choice of sclerosant for treatment of telangiectasia Simon Ashley, Plymouth, United Kingdom 17:12 to 17:20
Audience participation and discussion 17:20 to 17:30
ABDOMINAL AORTIC ANEURYSM CHALLENGES - Day 2 Wednesday 27 April
Chairman Andrew Holden, Auckland, New Zealand 08:00 to 09:36
Lifestyle and aneurysm growth Matt Thompson, London, United Kingdom 08:00 to 09:36
Lifestyle risk factors and risk to develop abdominal aortic aneurysm Martin Bjorck, Uppsala, Sweden 08:00 to 08:08
Ticagrelor and the inhibition of growth in small AAAs Anders Wanhainen, Uppsala, Sweden 08:08 to 08:18
ACE inhibitors and the inhibition of growth of small aneurysms Colin Bicknell, London, United Kingdom 08:16 to 08:24
Audience participation and discussion Jacques Busquet, Paris St Cloud, France 08:32 to 08:48
Chairman Andrew Holden, Auckland, New Zealand 08:48 to 09:36
Population screening challenges Matt Thompson, London, United Kingdom 08:48 to 09:36
National population-based AAA screening programmes remain a challenge for public health systems Vincent Riambau, Barcelona, Spain 08:48 to 08:56
The need for AAA screening to include examination of the common iliac arteries Martin Bjorck, Uppsala, Sweden 08:56 to 09:04
Aneurysm screening and the saving of lives Jonothan Earnshaw, Gloucester, United Kingdom 09:04 to 09:12
Audience participation and discussion 09:20 to 09:36
Chairman Andrew Holden, Auckland, New Zealand 09:36 to 10:28
The threshold for elective intervention for abdominal aortic and iliac aneurysm Matt Thompson, London, United Kingdom 09:36 to 10:28
Challenges in international harmonisation of AAA treatment Kevin Mani, Uppsala, Sweden 09:36 to 09:44
The changing epidemiology of abdominal aortic aneurysms in Europe David Sidloff, Leicester, United Kingdom 09:44 to 09:52
Audience participation and discussion 09:52 to 10:00
Chairman Dittmar Bockler, Heidelberg, Germany 10:03 to 10:28
Achieving precise placement, optimal seal and conformability in challenging aortic anatomies Robert Rhee, New York, United States 10:03 to 10:12
The benefits of conformable design in treating challenging thoracic pathologies William Jordan, Atlanta, United States 10:12 to 10:21
Audience participation and discussion 10:21 to 10:28
Chairman Martin Bjorck, Uppsala, Sweden 10:30 to 11:39
The threshold for elective intervention for abdominal aortic and iliac aneurysm (continued) Dittmar Bockler, Heidelberg, Germany 10:30 to 11:39
The reimbursement influence on practice Richard Grieve, London, United Kingdom 10:30 to 10:37
Internal iliac artery aneurysm does not rupture when the diameter is 3cm, but when it is 7cm Maarit Venermo, Helsinki, Finland 10:37 to 10:44
Publication of surgeon level results and risk aversion Ian Loftus, London, United Kingdom 10:44 to 10:51
Audience participation and discussion 10:51 to 11:03
Discussion and vote 11:23 to 11:39
Chairman Martin Bjorck, Uppsala, Sweden 11:39 to 12:30
Abdominal aortic technical challenges Dittmar Bockler, Heidelberg, Germany 11:39 to 12:30
Durability and iteration of Zenith series EVAR devices enable low profile development with safety Eric Verhoeven, Nuremberg, Germany 11:39 to 11:46
New delivery system improves EVAR experience Andrew Holden, Auckland, New Zealand 11:46 to 11:53
The clinical need for an iliac-branched endoprosthesis Michel Reijnen, Arnhem, Netherlands 11:53 to 12:00
Repositionable ultra-low profile EVAR system avoiding cannulation for simple deployment Dierk Scheinert, Leipzig, Germany 12:00 to 12:07
Preliminary results of the TREO phase II clinical trial Matthew J Eagleton, Cleveland, United States 12:07 to 12:14
12:14 to 12:30
Chairman Piergiorgio Cao, Rome, Italy 12:30 to 13:30
Reduced follow-up visits by protocol Matt Thompson, London, United Kingdom 12:33 to 12:39
Type 1 endoleak AND use of EndoAnchors for the failing endograft Jean-Paul de Vries, Nieuwegein, Netherlands 12:39 to 12:45
Evolution to lower profile whilst maintaining durability Hence Verhagen, Rotterdam, Netherlands 12:45 to 12:51
Audience participation and discussion 12:51 to 13:30
Chairman Roger Greenhalgh, London, United Kingdom 13:30 to 15:58
Current treatment of AAA in Germany - outcomes and trends in a five-year follow-up Sebastian Debus, Hamburg, Germany 14:55 to 15:02
Randomised controlled trial on effect of aneurysm sac embolisation for endoleak type II prevention Franco Grego, Padua, Italy 15:02 to 15:09
Arsenal aneurysm sac filling/sealing with any EVAR device Andrew Holden, Auckland, New Zealand 15:09 to 15:16
Type II endoleaks with enlarging aneurysms imply type I endoleak until disproved Michel Makaroun, Pittsburgh, United States 15:16 to 15:23
Audience participation and discussion 15:23 to 15:30
Chairman Timothy Resch, Malmo, Sweden 15:33 to 15:58
Prevention and management of type 1a endoleaks: EVAS vs. EVAR Michael Reijnen, Arnhem, Netherlands 15:33 to 15:39
Balloon expandable infrarenal neck changes neck diameter very little Dainis Krievins, Riga, Latvia 15:39 to 15:45
EVAS global clinical trial results Matt Thompson, London, United Kingdom 15:45 to 15:51
Audience participation and discussion 15:51 to 15:58
EVAR follow-up and avoidance of secondary sac rupture and death (continued) Sebastian Debus, Hamburg, Germany 16:00 to 16:52
Chairman Frans Moll, Utrecht, Netherlands 16:00 to 16:52
Debate: All the risk scores are useless for elective AAA Ron Balm, Amsterdam, Netherlands 16:00 to 16:12
Debate: All the risk scores are useless for elective AAA Matt Thompson, London, United Kingdom 16:00 to 16:12
Discussion and vote 16:12 to 16:24
The different appearance of endoleaks after EndoVascular Aneurysm Sealing (EVAS) Andrew Holden, Auckland, New Zealand 16:24 to 16:32
Latest generation device aneurysm - related mortality vs. benchmark EVAR 1 trial at four years Dittmar Bockler, Heidelberg, Germany 16:32 to 16:40
Comment: The use of Onyx for type II endoleak Robert Morgan, London, United Kingdom 16:40 to 16:42
Audience participation and discussion 16:42 to 16:52
Infected abdominal aortic aneurysm challenges Sebastian Debus, Hamburg, Germany 16:52 to 17:00
Chairman Frans Moll, Utrecht, Netherlands 16:52 to 17:00
Endo-VAC - a novel treatment option for infected vascular reconstructions Anders Wanhainen, Uppsala, Sweden 16:52 to 17:00
Ruptured abdominal aortic aneurysm Sebastian Debus, Hamburg, Germany 17:00 to 18:00
Chairman Frans Moll, Utrecht, Netherlands 17:00 to 18:00
Protocol approach before and after rupture improves outcome Benjamin Starnes, Seattle, United States 17:00 to 17:08
Fate of patients unwilling or unsuitable to undergo surgical interventions for ruptured abdominal aortic aneurysm (57 untreated patients) Ron Balm, Amsterdam, Netherlands 17:08 to 17:16
Developing a 48 hour mortality risk score for ruptured abdominal aortic aneurysm Michael Sweeting, Cambridge, United Kingdom 17:16 to 17:24
Benefits of local anaesthetic for ruptured AAA repair Robert Hinchliffe, London, United Kingdom 17:24 to 17:32
Increase the number of patients offered intervention for ruptured AAA Matt Thompson, London, United Kingdom 17:32 to 17:40
Audience participation and discussion 17:40 to 18:00
THORACIC AORTIC ANEURYSM CHALLENGES - Day 3 Thursday 28 April
Introduction Dittmar Bockler, Heidelberg, Germany 08:00 to 08:18
Chairman Matt Thompson, London, United Kingdom 08:00 to 08:18
Discussion and vote 08:12 to 08:18
Thoracic aneurysm challenges - risks of operative death and spinal cord ischaemia Dittmar Bockler, Heidelberg, Germany 08:18 to 10:28
Chairman Matt Thompson, London, United Kingdom 08:18 to 10:28
The Uppsala algorithm to prevent spinal cord ischaemia during extensive aortic surgery Anders Wanhainen, Uppsala, Sweden 08:18 to 08:26
Ascending, arch, descending and juxtarenal aortic reconstructive risks of operative death or spinal cord ischaemia with comparison of open and endovascular results Michael Jacobs, Maastricht, Netherlands 08:26 to 08:34
Low spinal cord ischaemia time with BEVAR and FEVAR is vital Eric Verhoeven, Nuremberg, Germany 08:34 to 08:42
Neurological consequences of endovascular aortic aneurysm surgery - EVAR and TEVAR Ruth Benson, Stoke On Trent, United Kingdom 08:42 to 08:50
Audience participation and discussion 08:50 to 09:05
Endovascular non-branched ascending aortic TEVAR with potential valve replacement: operative mortality and complications Rodney White, Torrance, United States 09:05 to 09:13
Aortic arch hybrid debranching Sebastian Debus, Hamburg, Germany 09:13 to 09:21
Dual branch use for the aortic arch Piergiorgio Cao, Rome, Italy 09:21 to 09:29
Single branch zone 0 Michel Makaroun, Pittsburgh, United States 09:29 to 09:37
Single branch zone 2 Michael Dake, Stanford, United States 09:37 to 09:45
Audience participation and discussion 09:45 to 10:00
Mini-symposium: Acute and chronic type B dissection - false lumen challenges Sebastian Debus, Hamburg, Germany 10:30 to 13:30
Chairman Roger Greenhalgh, London, United Kingdom 10:30 to 13:30
Following the structure of the descending aorta from two years before acute type B dissection Martin Czerny, Freiburg, Germany 10:30 to 10:38
Avoidance of retrograde type A dissection and aortic remodelling after Valiant Captivia TEVAR Dennis Gable, Dallas, United States 10:38 to 10:46
Impact of TEVAR on late mortality in chronic type B dissection Matt Thompson, London, United Kingdom 10:46 to 10:54
Predictors of intervention and mortality in patients with uncomplicated acute type B aortic dissection Ali Azizzadeh, Houston, United States 10:54 to 11:02
Audience participation and discussion 11:02 to 11:17
Aortic remodelling after standard TEVAR in chronic type B dissection Santi Trimarchi, San Donato Milanese, Italy 11:17 to 11:25
Retrospective analysis of chronic type B dissection treated intervention - future prediction of intervention defined Dittmar Bockler, Heidelberg, Germany 11:25 to 11:33
The legitimacy of embolisation of the false lumen Tara Mastracci, London, United Kingdom 11:33 to 11:41
Audience participation and discussion 11:41 to 11:56
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Fabrizio Fanelli, Rome, Italy 11:56 to 12:16
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Tilo Kolbel, Hamburg, Germany 11:56 to 12:16
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Jonathan Sobocinski, Lille, France 11:56 to 12:16
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Peter Mossop, Melbourne, Australia 11:56 to 12:16
Discussion and vote 12:16 to 12:30
TEVAR follow-up Dittmar Bockler, Heidelberg, Germany 13:30 to 14:25
Chairman Tara Mastracci, London, United Kingdom 13:30 to 14:25
15-year experience of TAA - similar 30-day mortality endovascular and open and similar paraplegia rates Roberto Chiesa, Milan, Italy 13:38 to 13:46
Long-term survival after TEVAR depends on indications Kevin Mani, Uppsala, Sweden 13:46 to 13:54
Five-year durability and outcomes of Valor II Rodney White, Torrance, United States 13:54 to 14:02
The optimal method of closure of large femoral artery holes after device introduction for percutaneous EVAR/ TEVAR Giovanni Pratesi, Florence, Italy 14:02 to 14:10
Audience participation and discussion 14:10 to 14:25
Mini-symposium: Radiation damage to the pioneer operators and methods to reduce radiation exposure during endovascular procedures Dittmar Bockler, Heidelberg, Germany 14:25 to 16:00
Chairman Tara Mastracci, London, United Kingdom 14:25 to 16:00
Introduction - the debt we owe to endovascular pioneers Roger Greenhalgh, London, United Kingdom 14:25 to 14:33
Methods to reduce radiation exposure during endovascular procedures Barry Katzen, Miami, United States 14:33 to 14:41
Endovascular total aorta replacement challenges Timothy Resch, Malmo, Sweden 14:41 to 14:49
Radiation protection training and reduction of radiation exposure to patients and staff Lars Lonn, Copenhagen, Denmark 14:49 to 14:57
Radiation dose associated with complex arch and thoracoabdominal interventions Fiona Rohlffs, Hamburg, Germany 14:57 to 15:05
Every effort is made to reduce radiation exposure whilst doing complex aortic endovascular reconstruction Stephan Haulon, Lille, France 15:05 to 15:13
Audience participation and discussion 15:13 to 15:30
Aortic transection challenges and a conundrum Richard Gibbs, London, United Kingdom 16:00 to 16:24
Chairman Andrew Holden, Auckland, New Zealand 16:00 to 16:24
Accurate placement of thoracic low-profile stent graft system for aortic transection Benjamin Starnes, Seattle, United States 16:00 to 16:08
The Kommerell Conundrum - diverticulum or aneurysm, and when and how to treat Frank Criado, Baltimore, United States 16:08 to 16:16
Audience participation and discussion 16:16 to 16:24
JUXTARENAL CHALLENGES - Day 3 Thursday 28 April
Challenging and short infrarenal neck Richard Gibbs, London, United Kingdom 16:24 to 17:54
Chairman Andrew Holden, Auckland, New Zealand 16:24 to 17:54
Treatment options for challenging EVAR utilising polymer ring technology Ventakesh Ramaiah, Phoenix, United States 16:24 to 16:32
A standard EVAR device can be used with EndoAnchor for aortic neck <10mm William Jordan, Atlanta, United States 16:32 to 16:40
The value of hybrid debranching Roberto Chiesa, Milan, Italy 16:40 to 16:48
EVAR repair with and without parallel graft use Ralf Kolvenbach, D'sseldorf, Germany 16:48 to 16:56
Use of polymer seal with complex aortic aneurysm necks and use of parallel grafts Matt Thompson, London, United Kingdom 16:56 to 17:04
Configuration affects parallel graft results Murray Shames, Tampa, United States 17:04 to 17:12
Audience participation and discussion 17:12 to 17:32
Audience participation and discussion 17:12 to 17:32
Debate: More than two parallel grafts relates to poorer outcome Konstantinos Donas, Munster, Germany 17:32 to 17:44
Debate: More than two parallel grafts relates to poorer outcome Frans Moll, Utrecht, Netherlands 17:32 to 17:44
ACUTE STROKE CHALLENGES - Day 4 Friday 29 April
Chairman Ross Naylor, Leicester, United Kingdom 08:00 to 08:57
Selection for intervention challenges Tommy Andersson, Kortrijk, Belgium 08:00 to 08:57
Screening men for asymptomatic carotid stenosis at the age of 65-70 Martin Bjorck, Uppsala, Sweden 08:00 to 08:06
Specialised imaging to identify high-risk plaque Clark Zeebregts, Groningen, Netherlands 08:06 to 08:12
Improvements in optimal medical care Martin Brown, London, United Kingdom 08:12 to 08:18
Algorithm of care or "stroke workflow" in acute stroke interventions Tudor Jovin, Pittsburgh, United States 08:18 to 08:24
Audience participation and discussion 08:24 to 08:32
Implications of the VAST randomised trial for managing symptomatic vertebrobasilar stenosis Jaap Kappelle, Utrecht, Netherlands 08:38 to 08:44
Microemboli and the cause of dementia Charles McCollum, Manchester, United Kingdom 08:44 to 08:50
Audience participation and discussion 08:50 to 08:57
Chairman Roger Greenhalgh, London, United Kingdom 08:57 to 10:30
Carotid stenting and endarterectomy Jos van den Berg, Lugano, Switzerland 08:57 to 10:30
Impact of risk scoring on decision-making in referral of symptomatic carotid stenosis for urgent revascularisation Martin Brown, London, United Kingdom 08:57 to 09:03
Impact of MicroNet technology on carotid revascularisation Piotr Musialek, Krakow, Poland 09:03 to 09:09
A modern stroke service must have timely access to carotid stenting if it is to offer optimal outcomes Trevor Cleveland, Sheffield, United Kingdom 09:09 to 09:15
Dual antiplatelet therapy reduces recurrent events prior to urgent carotid surgery without increasing the risk of perioperative bleeding complications Ross Naylor, Leicester, United Kingdom 09:15 to 09:21
Audience participation and discussion 09:21 to 09:29
Emergency stenting of the internal carotid artery with anterior circulation thrombectomy Daniel Behme, Gottingen, Germany 09:29 to 09:35
Urgent carotid endarterectomy does not increase risk and will prevent more strokes Ian Loftus, London, United Kingdom 09:35 to 09:41
Emergency carotid endarterectomy for progressing stroke Hans-Henning Eckstein, Munich, Germany 09:41 to 09:47
Carotid bypass using hybrid as a rescue technique for on-table failed carotid endarterectomy Domenico Valenti, London, United Kingdom 09:47 to 09:53
Audience participation and discussion 09:53 to 10:00
Chairman Martin Brown, London, United Kingdom 10:30 to 12:22
Intracranial clot retrieval Ross Naylor, Leicester, United Kingdom 10:30 to 12:22
Thrombectomy should be implemented in clinical practice - AHA/ASA guidelines Alexander Khalessi, San Diego, United States 10:30 to 10:40
Intra-arterial therapy in the early management of acute ischaemic stroke Jaap Kappelle, Utrecht, Netherlands 10:40 to 10:50
Selecting patients for acute endovascular cerebral clot extraction Laurent Spelle, Paris, France 10:50 to 11:00
Clot properties and technique may impact technical result and patient outcome Tommy Andersson, Kortrijk, Belgium 11:00 to 11:10
Multicentre experience with aspirational technique for acute stroke thrombectomy with ACE64 reperfusion catheter Annika Kowoll, Bochum, Germany 11:10 to 11:20
Stent retrieval (Solitaire) vs. Tissue Plasminogen Activator (tPA) - cost effectiveness Kyriakos Lobotesis, London, United Kingdom 11:20 to 11:30
Comment Tudor Jovin, Pittsburgh, United States 11:30 to 11:32
Audience participation and discussion 11:32 to 11:40
Debate: Only neuroradiologists should undertake intra-arterial thrombectomy Jos van den Berg, Lugano, Switzerland 11:40 to 11:58
Debate: Only neuroradiologists should undertake intra-arterial thrombectomy Andrew Clifton, London, United Kingdom 11:40 to 11:58
Discussion and vote 11:58 to 12:06
Chairman Martin Brown, London, United Kingdom 12:22 to 13:00
Cerebral embolisation reduction and arch protection devices Ross Naylor, Leicester, United Kingdom 12:22 to 13:00
Modified Transoesophageal Echocardiography imaging to assess thoracic aortic embolisation risk Arno Nierich, Zwolle, Netherlands 12:22 to 12:29
Changes to endovascular left subclavian artery implantation technique to reduce cerebral embolisation Frank Arko, Charlotte, United States 12:29 to 12:36
Avoidance of cerebral embolisation by aortic arch deflection of flow (TriGuard) Alexandra Lansky, New Haven, United States 12:36 to 12:43
The use of Sentinel cerebral protection filter system to prevent arch cerebral embolisation Richard Gibbs, London, United Kingdom 12:43 to 12:50
Audience participation and discussion 12:50 to 13:00
Introduction Iris Baumgartner, Bern, Switzerland 08:00 to 08:40
Chairman Cliff Shearman, Southampton, United Kingdom 08:00 to 08:40
Exercise therapy for claudicants - the guidance from NICE and other healthcare regulators is being ignored Jonathan Beard, Sheffield, United Kingdom 08:00 to 08:07
Wearable exercise tracker improves intermittent claudication Celia Riga, London, United Kingdom 08:07 to 08:14
Hypertension and the risk of peripheral arterial disease Kazem Rahimi, Oxford, United Kingdom 08:14 to 08:21
Debulking of arterial occlusions (Rotarex) Michael Lichtenberg, Arnsberg, Germany 08:21 to 08:28
Audience participation and discussion Jacques Busquet, Paris St Cloud, France 08:28 to 08:40
Chairman Roger Greenhalgh, London, United Kingdom 08:40 to 14:46
Superficial femoral artery Frans Moll, Utrecht, Netherlands 08:40 to 14:46
Rationale, evidence and indication for plaque modification before drug-coated balloon Erwin Blessing, Heidelberg, Germany 08:40 to 08:48
Technique and role of predilation in drug-coated balloon practice Stephan Duda, Berlin, Germany 08:48 to 08:56
Audience participation and discussion 08:56 to 09:04
Podium 1st: IN.PACT SFA two-year results - drug-coated balloon use in women and in diabetics Peter Schneider, Honolulu, United States 09:04 to 09:12
Arterial wall response to drug-coated balloon use Renu Virmani, Gaithersburg, United States 09:12 to 09:20
Outcomes from the German cohort in Levant 2 with procedural key issues Dierk Scheinert, Leipzig, Germany 09:20 to 09:28
Audience participation and discussion 09:28 to 09:36
ILLUMENATE global study - interim analysis Thomas Zeller, Bad Krozingen, Germany 09:36 to 09:44
Podium 1st : IN.PACT Global drug-coated balloon for complete total occlusion Gunnar Tepe, Rosenheim, Germany 09:44 to 09:52
Audience participation and discussion 09:52 to 10:00
Chairman Ramon Varcoe, Sydney, Australia 09:52 to 10:00
Stent characteristics overcome calcified lesions Enrique Puras Mallagray, Madrid, Spain 10:03 to 10:12
Economic benefit from avoiding reintervention Michael Jaff, Boston, United States 10:12 to 10:21
Audience participation and discussion 10:21 to 10:30
Chairman Roger Greenhalgh, London, United Kingdom 10:30 to 11:18
Stent challenges Giovanni Torsello, Muenster, Germany 10:30 to 11:18
Swirling flow is the aim for durable results Peter Gaines, Sheffield, United Kingdom 10:30 to 10:38
Radial strength and stent design can overcome calcified lesions Peter Goverde, Antwerp, Belgium 10:38 to 10:46
Zilver PTX - five-year results show the value of stent drug elution Michael Dake, Stanford, United States 10:46 to 10:54
The value of polymer release and paclitaxel combination with drug-eluting stents Juan Granada, Orangeburg, United States 10:54 to 11:02
Audience participation and discussion 11:02 to 11:18
Chairman Roger Greenhalgh, London, United Kingdom 11:18 to 12:30
The challenges of the long lesion Giovanni Torsello, Muenster, Germany 11:18 to 12:30
Drug-coated balloons for lesions >15cm Michael Jaff, Boston, United States 11:18 to 11:26
Atherectomy and drug-coated balloon for long and calcified lesions Thomas Zeller, Bad Krozingen, Germany 11:26 to 11:34
Sequential stents for long lesions Donald Jacobs, St. Louis, United States 11:34 to 11:42
Audience participation and discussion 11:42 to 11:54
Subintimal stent use for critical ischaemia and biphasic wave forms Luis Mariano Palena, Abano Terme, Italy 11:54 to 12:02
The use of a single long stent Peter Goverde, Antwerp, Belgium 12:02 to 12:10
The use of stent graft as a priority for lesions greater than 25cm Jorge Fernandez Noya, Santiago Compostela, Spain 12:10 to 12:18
Audience participation and discussion 12:18 to 12:30
Chairman Michael Jaff, Boston, United States 12:30 to 13:00
IN.PACT SFA two-year results of drug-coated balloon William Gray, Wynnewood, United States 12:33 to 12:42
EU healthcare economic analysis of IN.PACT SFA use Konstantinos Katsanos, London, United Kingdom 12:42 to 12:51
Audience participation and discussion 12:51 to 12:58
The challenges of in-stent restenosis Andrew Holden, Auckland, New Zealand 13:30 to 14:46
Chairman Frans Moll, Utrecht, Netherlands 13:30 to 14:46
Drug-coated balloons for in-stent restenosis Marianne Brodmann, Graz, Austria 13:30 to 13:37
Patterns are different for bare metal stent and drug-eluting stent which affect ease of management Gary Ansel, Columbus, United States 13:37 to 13:44
Any stent restenosis treated by stent graft Jeffrey Y Wang, Rockville, United States 13:44 to 13:51
Audience participation and discussion 13:51 to 14:01
Zilver PTX - interpretations of restenosis Thomas Zeller, Bad Krozingen, Germany 14:01 to 14:08
Treatment of iliac in-stent restenosis with laser debulking and covered stents Jos van den Berg, Lugano, Switzerland 14:08 to 14:15
Angioplasty alone or drug-coated balloon or laser debulk/drug-coated balloon for in-stent restenosis Eric Ducasse, Bordeaux, France 14:15 to 14:22
Ten-year follow-up of 1,000 patients with heparin-bonded PTFE Raffaele Pulli, Firenze, Italy 14:22 to 14:29
Audience participation and discussion 14:29 to 14:46
Popliteal aneurysm Andrew Holden, Auckland, New Zealand 14:46 to 14:58
Chairman Frans Moll, Utrecht, Netherlands 14:46 to 14:58
Popliteal aneurysm sac volume shrinkage after stent graft Michele Antonello, Padua, Italy 14:46 to 14:54
Audience participation and discussion 14:54 to 14:58
Audience participation and discussion 14:54 to 14:58
Below-the-knee Andrew Holden, Auckland, New Zealand 14:58 to 18:00
Chairman Frans Moll, Utrecht, Netherlands 14:58 to 18:00
Perfusion angiography for ischaemic tissue Jim Reekers, Amsterdam, Netherlands 14:58 to 15:06
Audience participation and discussion 15:06 to 15:14
Multi-modality advanced imaging for severe peripheral ischaemia Koen Deloose, Dendermonde, Belgium 15:14 to 15:22
Audience participation and discussion 15:22 to 15:30
Chairman Thomas Zeller, Bad Krozingen, Germany 16:00 to 16:52
Below-the-knee (Cont'd) Peter Schneider, Honolulu, United States 16:00 to 16:52
MRA calf perfusion before and after angioplasty Gerd Groezinger, Tubingen, Germany 16:00 to 16:08
First experience with a bioresorbable, Everolimus-eluting vascular scaffold in arteries below-the-knee Ramon Varcoe, Sydney, Australia 16:08 to 16:16
Angiosome concept in the treatment of critical limb ischaemia Maarit Venermo, Helsinki, Finland 16:16 to 16:24
A novel solution for below-the-knee arterial clot management for acute ischaemia Roberto Gandini, Rome, Italy 16:24 to 16:32
Ten-year results of pedal bypass surgery Anders Alback, Helsinki, Finland 16:32 to 16:40
Audience participation and discussion 16:40 to 16:52
Chairman Michael Edmonds, London, United Kingdom 16:52 to 18:00
Mini-symposium: Wound healing Cliff Shearman, Southampton, United Kingdom 16:52 to 18:00
The need to measure wound healing William Jeffcoate, Nottingham, United Kingdom 16:52 to 17:00
Early detection of ulceration in diabetic feet - an intelligent telemedicine system Jeff van Baal, ALMELO, Netherlands 17:00 to 17:08
The enduring principles of ulcer and wound healing in the ischaemic lower limb Malcolm Simms, Birmingham, United Kingdom 17:08 to 17:16
The use of autologous cell suspension for complex diabetic wounds Harvey Chant, Truro, United Kingdom 17:16 to 17:24
Adjunctive techniques including offloading and hyperbaric oxygen Andrew Boulton, Manchester, United Kingdom 17:24 to 17:32
Pulsating negative pressure to increase peripheral blood flow - mechanisms and potential clinical benefit Jonny Hisdal, Oslo, Norway 17:32 to 17:40
Audience participation and discussion 17:40 to 18:00
VENOUS CHALLENGES - Day 1 Tuesday 26 April
Chairman Stephen Black, East Horsley, United Kingdom 08:00 to 08:24
Deep vein thrombosis challenges Ian Franklin, London, United Kingdom 08:00 to 08:24
Protection from embolisation using Capturex Thomas Heller, Rostock, Germany 08:00 to 08:08
Vena cava filter Celect Platinum Richard McWilliams, Liverpool, United Kingdom 08:08 to 08:16
Audience participation and discussion 08:16 to 08:24
Acute deep vein thrombosis challenges Stephen Black, East Horsley, United Kingdom 08:24 to 14:18
Chairman Ian Franklin, London, United Kingdom 08:24 to 14:18
From venous thrombosis to post thrombotic syndrome Marzia Lugli, Modena, Italy 08:24 to 08:32
Deep vein thrombosis (DVT) in pregnancy Wilhelm Sandmann, Duisburg, Germany 08:32 to 08:40
Conservative management of DVT Gerry Stansby, Newcastle-upon-Tyne, United Kingdom 08:40 to 08:48
Investigating patients with acute DVT Karen Breen, London, United Kingdom 08:48 to 08:56
Ageing deep vein thrombosis Brahman Dharmarajah, London, United Kingdom 08:56 to 09:04
Audience participation and discussion 09:04 to 09:12
Selection of patients for acute DVT intervention Carsten Arnoldussen, Maastricht, Netherlands 09:12 to 09:20
Strategies for clot removal, lysis and mechanical thrombectomy Robert Thomas, London, United Kingdom 09:20 to 09:28
Deep venous catheter design (Zelante) for deep venous thrombectomy Gerard O'Sullivan, Galway, Ireland 09:28 to 09:36
Endovascular treatment for acute DVT and pulmonary embolism - Indigo System Michael Lichtenberg, Arnsberg, Germany 09:36 to 09:44
Detachment of occlusive thrombus in deep vein, aspiration, fragmentation and removal - Aspirex Thomas Heller, Rostock, Germany 09:44 to 09:52
Audience participation and discussion 09:52 to 10:00
Chairman Frans Moll, Utrecht, Netherlands 10:30 to 11:30
Acute deep vein thrombosis challenges (Cont'd) Gerry Stansby, Newcastle-upon-Tyne, United Kingdom 10:30 to 11:30
Deep vein stenting challenges 10:30 to 11:30
It is not just about patency - scales and quality of life outcomes Alun Davies, London, United Kingdom 10:30 to 10:38
VIDIO Trial - IVUS significantly improves diagnostic accuracy Paul Gagne, Darien, United States 10:38 to 10:46
Factors influencing outcome in venous stenting Stephen Black, East Horsley, United Kingdom 10:46 to 10:54
From lab to patient - strategies to improve stent patency Prakash Saha, London, United Kingdom 10:54 to 11:02
VIRTUS trial update on iliofemoral venous outflow obstruction Lowell Kabnick, Morristown, United States 11:02 to 11:10
Zilver Vena trial "first glimpse" Gerard O'Sullivan, Galway, Ireland 11:10 to 11:18
Audience participation and discussion 11:18 to 11:30
Proximal deep venous obstruction and pelvic vein reflux challenges 11:30 to 13:30
Deep venous stenting before superficial venous intervention Ian Franklin, London, United Kingdom 11:30 to 11:38
Selection of patients for pelvic vein intervention - which patients to treat and which patients to manage conservatively? Kathleen Gibson, Bellevue, United States 11:38 to 11:46
Male pattern pelvic reflux Previn Diwakar, Congleton, United Kingdom 11:46 to 11:54
Implications of pelvic vein embolisation for subsequent pregnancies Anthony Lopez, Guildford, United Kingdom 11:54 to 12:02
Pelvic vein embolisation for treatment of haemorrhoids David Beckett, Guildford, United Kingdom 12:02 to 12:10
Pathogenesis of haemorrhoids - colorectal surgeon's perspective Peter Dawson, London, United Kingdom 12:10 to 12:18
Audience participation and discussion 12:18 to 12:30
Chairman Mark Whiteley, Guildford, United Kingdom 13:30 to 14:18
Lymphoedema challenges Ian Franklin, London, United Kingdom 13:30 to 14:18
Lipoedema vs. lymphoedema Peter Mortimer, London, United Kingdom 13:38 to 13:46
Real-time, point-of-care lymphatic imaging Eva Sevick, Houston, United States 13:46 to 13:54
Silicone tubule implants for lower limb lymphoedema Rajesh Hydrabadi, Ahmedabad, India 13:54 to 14:02
Audience participation and discussion 14:02 to 14:18
Varicose vein challenges Mark Whiteley, Guildford, United Kingdom 14:18 to 17:30
Chairman Ian Franklin, London, United Kingdom 14:18 to 17:30
Ultrasound placed percutaneous clips will make CHIVA more widely applicable Lowell Kabnick, Morristown, United States 14:18 to 14:26
VeClose randomised controlled trial two-year follow-up Raghu Kolluri, Columbus, United States 14:26 to 14:34
Differences between great, small, accessory saphenous and Giacomini veins in terms of choice of technique for treating venous reflux Steve Elias, Englewood, United States 14:34 to 14:42
Audience participation and discussion 14:42 to 14:50
The future of bipolar radiofrequency thermal ablation Thomas Weiler, Pforzheim, Germany 14:50 to 14:58
The need to correct the accessory thigh vein and great saphenous vein even if only one incompetent Lowell Kabnick, Morristown, United States 14:58 to 15:06
Quality of life results in the use of cyanoacrylate adhesive embolisation Kathleen Gibson, Bellevue, United States 15:06 to 15:14
Audience participation and discussion 15:14 to 15:22
Chairman Manj Gohel, Cambridge, United Kingdom 15:33 to 15:58
eScope clinical trial - two and three year follow-up Thomas Proebstle, Hirschberg, Germany 15:33 to 15:42
VeClose roll-in patient results Raghu Kolluri, Columbus, United States 15:42 to 15:51
Audience participation and discussion 15:51 to 15:58
Chairman Alun Davies, London, United Kingdom 16:00 to 17:30
Varicose vein challenges (continued) Ian Franklin, London, United Kingdom 16:00 to 17:30
Role of antibiotics in varicose vein treatment Ian Chetter, Hull, United Kingdom 16:00 to 16:08
Venous wall thickness determines optimal choice of endovenous treatment Mark Whiteley, Guildford, United Kingdom 16:08 to 16:16
Management of anatomically difficult revascularisation Barrie Price, Guildford, United Kingdom 16:16 to 16:24
Anti-DVT prophylaxis for ambulatory varicose vein procedures Isaac Nyamekye, Worcester, United Kingdom 16:24 to 16:32
Sclerotherapy of the subulcer plexus - practical tips for success Manj Gohel, Cambridge, United Kingdom 16:32 to 16:40
Audience participation and discussion 16:40 to 16:48
Compression film bandage after sclerotherapy Johann Christof Ragg, Berlin, Germany 16:48 to 16:56
Strategies for getting the best cosmetic results for thread vein/telangiectasia treatment Thomas Proebstle, Hirschberg, Germany 16:56 to 17:04
Laser treatment of reticular and subcuticular veins Kasuo Miyake, Sao Paulo, Brazil 17:04 to 17:12
Evidence of choice of sclerosant for treatment of telangiectasia Simon Ashley, Plymouth, United Kingdom 17:12 to 17:20
Audience participation and discussion 17:20 to 17:30
ABDOMINAL AORTIC ANEURYSM CHALLENGES - Day 2 Wednesday 27 April
Chairman Andrew Holden, Auckland, New Zealand 08:00 to 09:36
Lifestyle and aneurysm growth Matt Thompson, London, United Kingdom 08:00 to 09:36
Lifestyle risk factors and risk to develop abdominal aortic aneurysm Martin Bjorck, Uppsala, Sweden 08:00 to 08:08
Ticagrelor and the inhibition of growth in small AAAs Anders Wanhainen, Uppsala, Sweden 08:08 to 08:18
ACE inhibitors and the inhibition of growth of small aneurysms Colin Bicknell, London, United Kingdom 08:16 to 08:24
Audience participation and discussion Jacques Busquet, Paris St Cloud, France 08:32 to 08:48
Chairman Andrew Holden, Auckland, New Zealand 08:48 to 09:36
Population screening challenges Matt Thompson, London, United Kingdom 08:48 to 09:36
National population-based AAA screening programmes remain a challenge for public health systems Vincent Riambau, Barcelona, Spain 08:48 to 08:56
The need for AAA screening to include examination of the common iliac arteries Martin Bjorck, Uppsala, Sweden 08:56 to 09:04
Aneurysm screening and the saving of lives Jonothan Earnshaw, Gloucester, United Kingdom 09:04 to 09:12
Audience participation and discussion 09:20 to 09:36
Chairman Andrew Holden, Auckland, New Zealand 09:36 to 10:28
The threshold for elective intervention for abdominal aortic and iliac aneurysm Matt Thompson, London, United Kingdom 09:36 to 10:28
Challenges in international harmonisation of AAA treatment Kevin Mani, Uppsala, Sweden 09:36 to 09:44
The changing epidemiology of abdominal aortic aneurysms in Europe David Sidloff, Leicester, United Kingdom 09:44 to 09:52
Audience participation and discussion 09:52 to 10:00
Chairman Dittmar Bockler, Heidelberg, Germany 10:03 to 10:28
Achieving precise placement, optimal seal and conformability in challenging aortic anatomies Robert Rhee, New York, United States 10:03 to 10:12
The benefits of conformable design in treating challenging thoracic pathologies William Jordan, Atlanta, United States 10:12 to 10:21
Audience participation and discussion 10:21 to 10:28
Chairman Martin Bjorck, Uppsala, Sweden 10:30 to 11:39
The threshold for elective intervention for abdominal aortic and iliac aneurysm (continued) Dittmar Bockler, Heidelberg, Germany 10:30 to 11:39
The reimbursement influence on practice Richard Grieve, London, United Kingdom 10:30 to 10:37
Internal iliac artery aneurysm does not rupture when the diameter is 3cm, but when it is 7cm Maarit Venermo, Helsinki, Finland 10:37 to 10:44
Publication of surgeon level results and risk aversion Ian Loftus, London, United Kingdom 10:44 to 10:51
Audience participation and discussion 10:51 to 11:03
Discussion and vote 11:23 to 11:39
Chairman Martin Bjorck, Uppsala, Sweden 11:39 to 12:30
Abdominal aortic technical challenges Dittmar Bockler, Heidelberg, Germany 11:39 to 12:30
Durability and iteration of Zenith series EVAR devices enable low profile development with safety Eric Verhoeven, Nuremberg, Germany 11:39 to 11:46
New delivery system improves EVAR experience Andrew Holden, Auckland, New Zealand 11:46 to 11:53
The clinical need for an iliac-branched endoprosthesis Michel Reijnen, Arnhem, Netherlands 11:53 to 12:00
Repositionable ultra-low profile EVAR system avoiding cannulation for simple deployment Dierk Scheinert, Leipzig, Germany 12:00 to 12:07
Preliminary results of the TREO phase II clinical trial Matthew J Eagleton, Cleveland, United States 12:07 to 12:14
12:14 to 12:30
Chairman Piergiorgio Cao, Rome, Italy 12:30 to 13:30
Reduced follow-up visits by protocol Matt Thompson, London, United Kingdom 12:33 to 12:39
Type 1 endoleak AND use of EndoAnchors for the failing endograft Jean-Paul de Vries, Nieuwegein, Netherlands 12:39 to 12:45
Evolution to lower profile whilst maintaining durability Hence Verhagen, Rotterdam, Netherlands 12:45 to 12:51
Audience participation and discussion 12:51 to 13:30
Chairman Roger Greenhalgh, London, United Kingdom 13:30 to 15:58
Current treatment of AAA in Germany - outcomes and trends in a five-year follow-up Sebastian Debus, Hamburg, Germany 14:55 to 15:02
Randomised controlled trial on effect of aneurysm sac embolisation for endoleak type II prevention Franco Grego, Padua, Italy 15:02 to 15:09
Arsenal aneurysm sac filling/sealing with any EVAR device Andrew Holden, Auckland, New Zealand 15:09 to 15:16
Type II endoleaks with enlarging aneurysms imply type I endoleak until disproved Michel Makaroun, Pittsburgh, United States 15:16 to 15:23
Audience participation and discussion 15:23 to 15:30
Chairman Timothy Resch, Malmo, Sweden 15:33 to 15:58
Prevention and management of type 1a endoleaks: EVAS vs. EVAR Michael Reijnen, Arnhem, Netherlands 15:33 to 15:39
Balloon expandable infrarenal neck changes neck diameter very little Dainis Krievins, Riga, Latvia 15:39 to 15:45
EVAS global clinical trial results Matt Thompson, London, United Kingdom 15:45 to 15:51
Audience participation and discussion 15:51 to 15:58
EVAR follow-up and avoidance of secondary sac rupture and death (continued) Sebastian Debus, Hamburg, Germany 16:00 to 16:52
Chairman Frans Moll, Utrecht, Netherlands 16:00 to 16:52
Debate: All the risk scores are useless for elective AAA Ron Balm, Amsterdam, Netherlands 16:00 to 16:12
Debate: All the risk scores are useless for elective AAA Matt Thompson, London, United Kingdom 16:00 to 16:12
Discussion and vote 16:12 to 16:24
The different appearance of endoleaks after EndoVascular Aneurysm Sealing (EVAS) Andrew Holden, Auckland, New Zealand 16:24 to 16:32
Latest generation device aneurysm - related mortality vs. benchmark EVAR 1 trial at four years Dittmar Bockler, Heidelberg, Germany 16:32 to 16:40
Comment: The use of Onyx for type II endoleak Robert Morgan, London, United Kingdom 16:40 to 16:42
Audience participation and discussion 16:42 to 16:52
Infected abdominal aortic aneurysm challenges Sebastian Debus, Hamburg, Germany 16:52 to 17:00
Chairman Frans Moll, Utrecht, Netherlands 16:52 to 17:00
Endo-VAC - a novel treatment option for infected vascular reconstructions Anders Wanhainen, Uppsala, Sweden 16:52 to 17:00
Ruptured abdominal aortic aneurysm Sebastian Debus, Hamburg, Germany 17:00 to 18:00
Chairman Frans Moll, Utrecht, Netherlands 17:00 to 18:00
Protocol approach before and after rupture improves outcome Benjamin Starnes, Seattle, United States 17:00 to 17:08
Fate of patients unwilling or unsuitable to undergo surgical interventions for ruptured abdominal aortic aneurysm (57 untreated patients) Ron Balm, Amsterdam, Netherlands 17:08 to 17:16
Developing a 48 hour mortality risk score for ruptured abdominal aortic aneurysm Michael Sweeting, Cambridge, United Kingdom 17:16 to 17:24
Benefits of local anaesthetic for ruptured AAA repair Robert Hinchliffe, London, United Kingdom 17:24 to 17:32
Increase the number of patients offered intervention for ruptured AAA Matt Thompson, London, United Kingdom 17:32 to 17:40
Audience participation and discussion 17:40 to 18:00
THORACIC AORTIC ANEURYSM CHALLENGES - Day 3 Thursday 28 April
Introduction Dittmar Bockler, Heidelberg, Germany 08:00 to 08:18
Chairman Matt Thompson, London, United Kingdom 08:00 to 08:18
Discussion and vote 08:12 to 08:18
Thoracic aneurysm challenges - risks of operative death and spinal cord ischaemia Dittmar Bockler, Heidelberg, Germany 08:18 to 10:28
Chairman Matt Thompson, London, United Kingdom 08:18 to 10:28
The Uppsala algorithm to prevent spinal cord ischaemia during extensive aortic surgery Anders Wanhainen, Uppsala, Sweden 08:18 to 08:26
Ascending, arch, descending and juxtarenal aortic reconstructive risks of operative death or spinal cord ischaemia with comparison of open and endovascular results Michael Jacobs, Maastricht, Netherlands 08:26 to 08:34
Low spinal cord ischaemia time with BEVAR and FEVAR is vital Eric Verhoeven, Nuremberg, Germany 08:34 to 08:42
Neurological consequences of endovascular aortic aneurysm surgery - EVAR and TEVAR Ruth Benson, Stoke On Trent, United Kingdom 08:42 to 08:50
Audience participation and discussion 08:50 to 09:05
Endovascular non-branched ascending aortic TEVAR with potential valve replacement: operative mortality and complications Rodney White, Torrance, United States 09:05 to 09:13
Aortic arch hybrid debranching Sebastian Debus, Hamburg, Germany 09:13 to 09:21
Dual branch use for the aortic arch Piergiorgio Cao, Rome, Italy 09:21 to 09:29
Single branch zone 0 Michel Makaroun, Pittsburgh, United States 09:29 to 09:37
Single branch zone 2 Michael Dake, Stanford, United States 09:37 to 09:45
Audience participation and discussion 09:45 to 10:00
Mini-symposium: Acute and chronic type B dissection - false lumen challenges Sebastian Debus, Hamburg, Germany 10:30 to 13:30
Chairman Roger Greenhalgh, London, United Kingdom 10:30 to 13:30
Following the structure of the descending aorta from two years before acute type B dissection Martin Czerny, Freiburg, Germany 10:30 to 10:38
Avoidance of retrograde type A dissection and aortic remodelling after Valiant Captivia TEVAR Dennis Gable, Dallas, United States 10:38 to 10:46
Impact of TEVAR on late mortality in chronic type B dissection Matt Thompson, London, United Kingdom 10:46 to 10:54
Predictors of intervention and mortality in patients with uncomplicated acute type B aortic dissection Ali Azizzadeh, Houston, United States 10:54 to 11:02
Audience participation and discussion 11:02 to 11:17
Aortic remodelling after standard TEVAR in chronic type B dissection Santi Trimarchi, San Donato Milanese, Italy 11:17 to 11:25
Retrospective analysis of chronic type B dissection treated intervention - future prediction of intervention defined Dittmar Bockler, Heidelberg, Germany 11:25 to 11:33
The legitimacy of embolisation of the false lumen Tara Mastracci, London, United Kingdom 11:33 to 11:41
Audience participation and discussion 11:41 to 11:56
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Fabrizio Fanelli, Rome, Italy 11:56 to 12:16
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Tilo Kolbel, Hamburg, Germany 11:56 to 12:16
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Jonathan Sobocinski, Lille, France 11:56 to 12:16
Great Debate: In chronic type B dissection, there is no place for false lumen embolisation - true lumen TEVAR is preferred Peter Mossop, Melbourne, Australia 11:56 to 12:16
Discussion and vote 12:16 to 12:30
TEVAR follow-up Dittmar Bockler, Heidelberg, Germany 13:30 to 14:25
Chairman Tara Mastracci, London, United Kingdom 13:30 to 14:25
15-year experience of TAA - similar 30-day mortality endovascular and open and similar paraplegia rates Roberto Chiesa, Milan, Italy 13:38 to 13:46
Long-term survival after TEVAR depends on indications Kevin Mani, Uppsala, Sweden 13:46 to 13:54
Five-year durability and outcomes of Valor II Rodney White, Torrance, United States 13:54 to 14:02
The optimal method of closure of large femoral artery holes after device introduction for percutaneous EVAR/ TEVAR Giovanni Pratesi, Florence, Italy 14:02 to 14:10
Audience participation and discussion 14:10 to 14:25
Mini-symposium: Radiation damage to the pioneer operators and methods to reduce radiation exposure during endovascular procedures Dittmar Bockler, Heidelberg, Germany 14:25 to 16:00
Chairman Tara Mastracci, London, United Kingdom 14:25 to 16:00
Introduction - the debt we owe to endovascular pioneers Roger Greenhalgh, London, United Kingdom 14:25 to 14:33
Methods to reduce radiation exposure during endovascular procedures Barry Katzen, Miami, United States 14:33 to 14:41
Endovascular total aorta replacement challenges Timothy Resch, Malmo, Sweden 14:41 to 14:49
Radiation protection training and reduction of radiation exposure to patients and staff Lars Lonn, Copenhagen, Denmark 14:49 to 14:57
Radiation dose associated with complex arch and thoracoabdominal interventions Fiona Rohlffs, Hamburg, Germany 14:57 to 15:05
Every effort is made to reduce radiation exposure whilst doing complex aortic endovascular reconstruction Stephan Haulon, Lille, France 15:05 to 15:13
Audience participation and discussion 15:13 to 15:30
Aortic transection challenges and a conundrum Richard Gibbs, London, United Kingdom 16:00 to 16:24
Chairman Andrew Holden, Auckland, New Zealand 16:00 to 16:24
Accurate placement of thoracic low-profile stent graft system for aortic transection Benjamin Starnes, Seattle, United States 16:00 to 16:08
The Kommerell Conundrum - diverticulum or aneurysm, and when and how to treat Frank Criado, Baltimore, United States 16:08 to 16:16
Audience participation and discussion 16:16 to 16:24
JUXTARENAL CHALLENGES - Day 3 Thursday 28 April
Challenging and short infrarenal neck Richard Gibbs, London, United Kingdom 16:24 to 17:54
Chairman Andrew Holden, Auckland, New Zealand 16:24 to 17:54
Treatment options for challenging EVAR utilising polymer ring technology Ventakesh Ramaiah, Phoenix, United States 16:24 to 16:32
A standard EVAR device can be used with EndoAnchor for aortic neck <10mm William Jordan, Atlanta, United States 16:32 to 16:40
The value of hybrid debranching Roberto Chiesa, Milan, Italy 16:40 to 16:48
EVAR repair with and without parallel graft use Ralf Kolvenbach, D'sseldorf, Germany 16:48 to 16:56
Use of polymer seal with complex aortic aneurysm necks and use of parallel grafts Matt Thompson, London, United Kingdom 16:56 to 17:04
Configuration affects parallel graft results Murray Shames, Tampa, United States 17:04 to 17:12
Audience participation and discussion 17:12 to 17:32
Audience participation and discussion 17:12 to 17:32
Debate: More than two parallel grafts relates to poorer outcome Konstantinos Donas, Munster, Germany 17:32 to 17:44
Debate: More than two parallel grafts relates to poorer outcome Frans Moll, Utrecht, Netherlands 17:32 to 17:44
ACUTE STROKE CHALLENGES - Day 4 Friday 29 April
Chairman Ross Naylor, Leicester, United Kingdom 08:00 to 08:57
Selection for intervention challenges Tommy Andersson, Kortrijk, Belgium 08:00 to 08:57
Screening men for asymptomatic carotid stenosis at the age of 65-70 Martin Bjorck, Uppsala, Sweden 08:00 to 08:06
Specialised imaging to identify high-risk plaque Clark Zeebregts, Groningen, Netherlands 08:06 to 08:12
Improvements in optimal medical care Martin Brown, London, United Kingdom 08:12 to 08:18
Algorithm of care or "stroke workflow" in acute stroke interventions Tudor Jovin, Pittsburgh, United States 08:18 to 08:24
Audience participation and discussion 08:24 to 08:32
Implications of the VAST randomised trial for managing symptomatic vertebrobasilar stenosis Jaap Kappelle, Utrecht, Netherlands 08:38 to 08:44
Microemboli and the cause of dementia Charles McCollum, Manchester, United Kingdom 08:44 to 08:50
Audience participation and discussion 08:50 to 08:57
Chairman Roger Greenhalgh, London, United Kingdom 08:57 to 10:30
Carotid stenting and endarterectomy Jos van den Berg, Lugano, Switzerland 08:57 to 10:30
Impact of risk scoring on decision-making in referral of symptomatic carotid stenosis for urgent revascularisation Martin Brown, London, United Kingdom 08:57 to 09:03
Impact of MicroNet technology on carotid revascularisation Piotr Musialek, Krakow, Poland 09:03 to 09:09
A modern stroke service must have timely access to carotid stenting if it is to offer optimal outcomes Trevor Cleveland, Sheffield, United Kingdom 09:09 to 09:15
Dual antiplatelet therapy reduces recurrent events prior to urgent carotid surgery without increasing the risk of perioperative bleeding complications Ross Naylor, Leicester, United Kingdom 09:15 to 09:21
Audience participation and discussion 09:21 to 09:29
Emergency stenting of the internal carotid artery with anterior circulation thrombectomy Daniel Behme, Gottingen, Germany 09:29 to 09:35
Urgent carotid endarterectomy does not increase risk and will prevent more strokes Ian Loftus, London, United Kingdom 09:35 to 09:41
Emergency carotid endarterectomy for progressing stroke Hans-Henning Eckstein, Munich, Germany 09:41 to 09:47
Carotid bypass using hybrid as a rescue technique for on-table failed carotid endarterectomy Domenico Valenti, London, United Kingdom 09:47 to 09:53
Audience participation and discussion 09:53 to 10:00
Chairman Martin Brown, London, United Kingdom 10:30 to 12:22
Intracranial clot retrieval Ross Naylor, Leicester, United Kingdom 10:30 to 12:22
Thrombectomy should be implemented in clinical practice - AHA/ASA guidelines Alexander Khalessi, San Diego, United States 10:30 to 10:40
Intra-arterial therapy in the early management of acute ischaemic stroke Jaap Kappelle, Utrecht, Netherlands 10:40 to 10:50
Selecting patients for acute endovascular cerebral clot extraction Laurent Spelle, Paris, France 10:50 to 11:00
Clot properties and technique may impact technical result and patient outcome Tommy Andersson, Kortrijk, Belgium 11:00 to 11:10
Multicentre experience with aspirational technique for acute stroke thrombectomy with ACE64 reperfusion catheter Annika Kowoll, Bochum, Germany 11:10 to 11:20
Stent retrieval (Solitaire) vs. Tissue Plasminogen Activator (tPA) - cost effectiveness Kyriakos Lobotesis, London, United Kingdom 11:20 to 11:30
Comment Tudor Jovin, Pittsburgh, United States 11:30 to 11:32
Audience participation and discussion 11:32 to 11:40
Debate: Only neuroradiologists should undertake intra-arterial thrombectomy Jos van den Berg, Lugano, Switzerland 11:40 to 11:58
Debate: Only neuroradiologists should undertake intra-arterial thrombectomy Andrew Clifton, London, United Kingdom 11:40 to 11:58
Discussion and vote 11:58 to 12:06
Chairman Martin Brown, London, United Kingdom 12:22 to 13:00
Cerebral embolisation reduction and arch protection devices Ross Naylor, Leicester, United Kingdom 12:22 to 13:00
Modified Transoesophageal Echocardiography imaging to assess thoracic aortic embolisation risk Arno Nierich, Zwolle, Netherlands 12:22 to 12:29
Changes to endovascular left subclavian artery implantation technique to reduce cerebral embolisation Frank Arko, Charlotte, United States 12:29 to 12:36
Avoidance of cerebral embolisation by aortic arch deflection of flow (TriGuard) Alexandra Lansky, New Haven, United States 12:36 to 12:43
The use of Sentinel cerebral protection filter system to prevent arch cerebral embolisation Richard Gibbs, London, United Kingdom 12:43 to 12:50
Audience participation and discussion 12:50 to 13:00
Industry Sponsored Satellite - Vascutek
Thursday 28 April
Chairman Andrea Stella, Bologna, Italy 12:33 to 13:25
FEVAR does not impair renal function more than open surgery for juxtarenal aortic aneurysms Jan Brunkwall, Koln, Germany 12:33 to 12:43
Discussion 12:43 to 12:46
3D Prototyping for FEVAR - technical implications and clinical relevance Afshin Assadian, Vienna, Austria 12:46 to 12:56
Discussion 12:56 to 12:59
Video of Anaconda implantation - infrarenal neck angulation up to 90? Donald Reid, Wishaw, United Kingdom 12:59 to 13:09
Discussion 13:09 to 13:12
The Dutch experience - mid-term follow-up of Fenestrated Anaconda Clark Zeebregts, Groningen, Netherlands 13:12 to 13:22
Discussion 13:22 to 13:25
Industry Sponsored Satellite - Maquet Tuesday 26 April
Prevention of (endo)vascular graft infections - Soaking or Coating? Fatima Mzali, Bordeaux, France 13:03 to 13:12
New evidence of the antimicrobial efficacy of INTERGARD SYNERGY grafts Xavier Berard, Bordeaux, France 13:12 to 13:21
Thursday 28 April
Improving the outcome of your complex procedures in combination with the Advanta V12 covered stent Jean-Paul de Vries, Nieuwegein, Netherlands 15:33 to 15:58
Tips and tricks: how to treat aortoiliac stenosis by the CERAB technique Peter Goverde, Antwerp, Belgium 15:43 to 15:52
Discussion 15:52 to 15:58
Chairman Andrea Stella, Bologna, Italy 12:33 to 13:25
FEVAR does not impair renal function more than open surgery for juxtarenal aortic aneurysms Jan Brunkwall, Koln, Germany 12:33 to 12:43
Discussion 12:43 to 12:46
3D Prototyping for FEVAR - technical implications and clinical relevance Afshin Assadian, Vienna, Austria 12:46 to 12:56
Discussion 12:56 to 12:59
Video of Anaconda implantation - infrarenal neck angulation up to 90? Donald Reid, Wishaw, United Kingdom 12:59 to 13:09
Discussion 13:09 to 13:12
The Dutch experience - mid-term follow-up of Fenestrated Anaconda Clark Zeebregts, Groningen, Netherlands 13:12 to 13:22
Discussion 13:22 to 13:25
Industry Sponsored Satellite - Maquet Tuesday 26 April
Prevention of (endo)vascular graft infections - Soaking or Coating? Fatima Mzali, Bordeaux, France 13:03 to 13:12
New evidence of the antimicrobial efficacy of INTERGARD SYNERGY grafts Xavier Berard, Bordeaux, France 13:12 to 13:21
Thursday 28 April
Improving the outcome of your complex procedures in combination with the Advanta V12 covered stent Jean-Paul de Vries, Nieuwegein, Netherlands 15:33 to 15:58
Tips and tricks: how to treat aortoiliac stenosis by the CERAB technique Peter Goverde, Antwerp, Belgium 15:43 to 15:52
Discussion 15:52 to 15:58
CX Peripheral Live and Edited Cases
Wednesday 27 April
CX Peripheral Live and Edited Cases Thomas Zeller, Bad Krozingen, Germany 10:30 to 12:30
CX Peripheral Live and Edited Cases Giovanni Torsello, Muenster, Germany 10:30 to 12:30
Chairman Michael Jaff, Boston, United States 10:30 to 12:30
IN.PACT Drug-coated balloon for long lesions Antonio Micari, Palermo, Italy 10:30 to 11:00
AngioSculpt followed by drug coated balloon-LIVE CASE Theodosios Bisdas, Munster, Germany 11:00 to 11:30
Jetstream Atherectomy and Ranger drug-coated balloon in restenosis of bare metal stent Fabrizio Fanelli, Rome, Italy 11:30 to 12:00
Rotarex use for arterial occlusion-LIVE CASE Arne Schwindt, Munster, Germany 12:00 to 12:30
Rotarex use for arterial occlusion-LIVE CASE Theodosios Bisdas, Munster, Germany 12:00 to 12:30
CX Peripheral Live and Edited Cases (continued) Thomas Zeller, Bad Krozingen, Germany 13:30 to 15:45
Giovanni Torsello, Muenster, Germany 13:30 to 15:45
Chairman Robert Morgan, London, United Kingdom 13:30 to 15:45
The deployment of the Zilver PTX drug eluting stent-LIVE CASE Arne Schwindt, Munster, Germany 13:30 to 14:00
The deployment of the Zilver PTX drug eluting stent-LIVE CASE Theodosios Bisdas, Munster, Germany 13:30 to 14:00
The value of the Tigris dual component stent Bertrand Saint-Lebes, Toulouse, France 14:00 to 14:30
SUPERA - stent for calcified artery without pre-treatment-LIVE CASE Arne Schwindt, Munster, Germany 14:30 to 15:15
SUPERA - stent for calcified artery without pre-treatment-LIVE CASE Theodosios Bisdas, Munster, Germany 14:30 to 15:15
CX Peripheral Live and Edited Cases (continued) Thomas Zeller, Bad Krozingen, Germany 15:45 to 17:30
CX Peripheral Live and Edited Cases (continued) Giovanni Torsello, Muenster, Germany 15:45 to 17:30
Chairman Michael Jaff, Boston, United States 15:45 to 17:30
The deployment of the Eluvia drug eluting stent-LIVE CASE Arne Schwindt, Munster, Germany 15:45 to 16:15
The deployment of the Eluvia drug eluting stent-LIVE CASE Theodosios Bisdas, Munster, Germany 15:45 to 16:15
Viabahn stent graft for popliteal aneurysm Michele Antonello, Padua, Italy 16:15 to 16:45
HawkOne atherectomy and IN.PACT Drug coated balloon- LIVE CASE Arne Schwindt, Munster, Germany 16:45 to 17:30
HawkOne atherectomy and IN.PACT Drug coated balloon- LIVE CASE Theodosios Bisdas, Munster, Germany 16:45 to 17:30
CX Peripheral Live and Edited Cases Thomas Zeller, Bad Krozingen, Germany 10:30 to 12:30
CX Peripheral Live and Edited Cases Giovanni Torsello, Muenster, Germany 10:30 to 12:30
Chairman Michael Jaff, Boston, United States 10:30 to 12:30
IN.PACT Drug-coated balloon for long lesions Antonio Micari, Palermo, Italy 10:30 to 11:00
AngioSculpt followed by drug coated balloon-LIVE CASE Theodosios Bisdas, Munster, Germany 11:00 to 11:30
Jetstream Atherectomy and Ranger drug-coated balloon in restenosis of bare metal stent Fabrizio Fanelli, Rome, Italy 11:30 to 12:00
Rotarex use for arterial occlusion-LIVE CASE Arne Schwindt, Munster, Germany 12:00 to 12:30
Rotarex use for arterial occlusion-LIVE CASE Theodosios Bisdas, Munster, Germany 12:00 to 12:30
CX Peripheral Live and Edited Cases (continued) Thomas Zeller, Bad Krozingen, Germany 13:30 to 15:45
Giovanni Torsello, Muenster, Germany 13:30 to 15:45
Chairman Robert Morgan, London, United Kingdom 13:30 to 15:45
The deployment of the Zilver PTX drug eluting stent-LIVE CASE Arne Schwindt, Munster, Germany 13:30 to 14:00
The deployment of the Zilver PTX drug eluting stent-LIVE CASE Theodosios Bisdas, Munster, Germany 13:30 to 14:00
The value of the Tigris dual component stent Bertrand Saint-Lebes, Toulouse, France 14:00 to 14:30
SUPERA - stent for calcified artery without pre-treatment-LIVE CASE Arne Schwindt, Munster, Germany 14:30 to 15:15
SUPERA - stent for calcified artery without pre-treatment-LIVE CASE Theodosios Bisdas, Munster, Germany 14:30 to 15:15
CX Peripheral Live and Edited Cases (continued) Thomas Zeller, Bad Krozingen, Germany 15:45 to 17:30
CX Peripheral Live and Edited Cases (continued) Giovanni Torsello, Muenster, Germany 15:45 to 17:30
Chairman Michael Jaff, Boston, United States 15:45 to 17:30
The deployment of the Eluvia drug eluting stent-LIVE CASE Arne Schwindt, Munster, Germany 15:45 to 16:15
The deployment of the Eluvia drug eluting stent-LIVE CASE Theodosios Bisdas, Munster, Germany 15:45 to 16:15
Viabahn stent graft for popliteal aneurysm Michele Antonello, Padua, Italy 16:15 to 16:45
HawkOne atherectomy and IN.PACT Drug coated balloon- LIVE CASE Arne Schwindt, Munster, Germany 16:45 to 17:30
HawkOne atherectomy and IN.PACT Drug coated balloon- LIVE CASE Theodosios Bisdas, Munster, Germany 16:45 to 17:30
CX Aortic Edited Cases
Thursday 28 April
Chairman Roger Greenhalgh, London, United Kingdom 08:30 to 10:00
Thoracic aortic Andrew Holden, Auckland, New Zealand 08:30 to 10:00
TAG Thoracic Branch Endoprosthesis for the arch Michael Dake, Stanford, United States 08:30 to 09:00
Thoracic proximal scallop stent graft: expanding proximal neck in patients with challenging thoracic anatomy Jos van den Berg, Lugano, Switzerland 09:00 to 09:30
Zenith Alpha Thoracic: treating a thoracic aneurysm with a modular system Eric Verhoeven, Nuremberg, Germany 09:30 to 10:00
Abdominal aortic Andrew Holden, Auckland, New Zealand 10:30 to 12:30
Chairman Frans Moll, Utrecht, Netherlands 10:30 to 12:30
Zenith Alpha Abdominal: an easy way to deploy endografts to treat a wider range of patients Mauro Gargiulo, Bologna, Italy 11:00 to 11:30
Pre-operative intent of use of EndoAnchor for neck length <10mm William Jordan, Atlanta, United States 12:00 to 12:30
Abdominal aortic (continued) Michael Dake, Stanford, United States 13:30 to 16:00
Chairman Matt Thompson, London, United Kingdom 13:30 to 16:00
Special techniques of EVAS/Nellix Andrew Holden, Auckland, New Zealand 13:30 to 14:00
EXCLUDER iliac branch endoprosthesis Michel Makaroun, Pittsburgh, United States 14:00 to 14:30
Infected EVAR. Infection control with open repair using INTERGARD SYNERGY Xavier Berard, Bordeaux, France 14:30 to 15:00
Onyx liquid embolic system embolization for type II endoleaks Arne Schwindt, Munster, Germany 15:00 to 15:30
Chairman Roger Greenhalgh, London, United Kingdom 08:30 to 10:00
Thoracic aortic Andrew Holden, Auckland, New Zealand 08:30 to 10:00
TAG Thoracic Branch Endoprosthesis for the arch Michael Dake, Stanford, United States 08:30 to 09:00
Thoracic proximal scallop stent graft: expanding proximal neck in patients with challenging thoracic anatomy Jos van den Berg, Lugano, Switzerland 09:00 to 09:30
Zenith Alpha Thoracic: treating a thoracic aneurysm with a modular system Eric Verhoeven, Nuremberg, Germany 09:30 to 10:00
Abdominal aortic Andrew Holden, Auckland, New Zealand 10:30 to 12:30
Chairman Frans Moll, Utrecht, Netherlands 10:30 to 12:30
Zenith Alpha Abdominal: an easy way to deploy endografts to treat a wider range of patients Mauro Gargiulo, Bologna, Italy 11:00 to 11:30
Pre-operative intent of use of EndoAnchor for neck length <10mm William Jordan, Atlanta, United States 12:00 to 12:30
Abdominal aortic (continued) Michael Dake, Stanford, United States 13:30 to 16:00
Chairman Matt Thompson, London, United Kingdom 13:30 to 16:00
Special techniques of EVAS/Nellix Andrew Holden, Auckland, New Zealand 13:30 to 14:00
EXCLUDER iliac branch endoprosthesis Michel Makaroun, Pittsburgh, United States 14:00 to 14:30
Infected EVAR. Infection control with open repair using INTERGARD SYNERGY Xavier Berard, Bordeaux, France 14:30 to 15:00
Onyx liquid embolic system embolization for type II endoleaks Arne Schwindt, Munster, Germany 15:00 to 15:30